{"id":1565,"date":"1999-01-01T12:04:00","date_gmt":"1999-01-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/leserbrief-european-stroke-prevention-study-2-esps-2"},"modified":"1999-01-01T12:04:00","modified_gmt":"1999-01-01T11:04:00","slug":"leserbrief-european-stroke-prevention-study-2-esps-2","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/leserbrief-european-stroke-prevention-study-2-esps-2","title":{"rendered":"Leserbrief: European Stroke Prevention Study 2 (ESPS-2)"},"content":{"rendered":"<p>Frau Dr. U.M. aus Ingelheim schreibt: >> In Ihrer kleinen Mitteilung &#8222;Neues zur Sekund\u00e4rprophylaxe des isch\u00e4mischen Insults&#8220; (AMB 1998, 32, 84) wurde die European Stroke Prevention Study (ESPS-2), durchgef\u00fchrt mit der Kombination aus retardiertem Dipyridamol 200 mg und ASS 25 mg 2mal t\u00e4gl., versehentlich als ECASS-II-Studie bezeichnet; dies ist jedoch eine andere Studie mit dem [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frau Dr. U.M. aus Ingelheim schreibt: >> In Ihrer kleinen Mitteilung &#8222;Neues zur Sekund\u00e4rprophylaxe des isch\u00e4mischen Insults&#8220; (AMB 1998, 32, 84) wurde die European Stroke Prevention Study (ESPS-2), durchgef\u00fchrt mit der Kombination aus retardiertem Dipyridamol 200 mg und ASS 25 mg 2mal t\u00e4gl., versehentlich als ECASS-II-Studie bezeichnet; dies ist jedoch eine andere Studie mit dem [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,60,77,76,590,1591,68,56],"class_list":["post-1565","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-apoplektischer-insult","tag-ass","tag-azetylsalizylsaeure","tag-dipyridamol","tag-esps-2-studie","tag-hirninfarkt","tag-schlaganfall"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1565"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1565\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}